Cybin Collaborates with Osmind for Psychiatry Program Preparation

Cybin Inc., a company dedicated to transforming mental healthcare with innovative treatments, has announced a strategic alliance with Osmind, a prominent provider of technological and service-based solutions advancing psychiatry. This collaboration is aimed at enhancing the commercialization efforts for Cybin's clinical-stage programs by leveraging Osmind's extensive network of over 800 psychiatry clinics in the United States.

Doug Drysdale, CEO of Cybin, emphasized the importance of this partnership in preparing for the commercialization of their clinical-stage programs. By aligning with Osmind, Cybin aims to accelerate its operational infrastructure development, particularly in areas critical to interventional treatments. This includes mapping clinic workflows, pharmacy processes, patient access, and reimbursement systems. Cybin's leading programs, CYB003 and CYB004, are currently in the advanced stages of clinical trials for major depressive disorder and generalized anxiety disorder, respectively. The collaboration is expected to facilitate a smoother transition to market, ultimately transforming treatment options for mental health disorders.

Mental health remains a significant challenge in the United States, with approximately 52.9 million individuals affected by mental illnesses. The existing standard of care does not provide relief for many patients, underscoring the necessity for novel therapeutic solutions. Jimmy Qian, President of Osmind, expressed enthusiasm for the partnership, highlighting the alignment of both companies' missions to provide advanced mental health treatments to a broader audience. By preparing real-world settings for next-generation neuropsychiatric interventions, Osmind aims to reduce barriers for clinicians and improve patient access, thereby supporting Cybin's market entry and expansion.

Globally, mental health issues like major depressive disorder (MDD) and generalized anxiety disorder (GAD) continue to affect millions. Over 300 million people worldwide suffer from MDD, and the market for its treatment is projected to grow significantly in the coming decade. In the U.S., around 21 million individuals have experienced a major depressive episode, with two-thirds not finding relief from initial antidepressant treatments. Additionally, 6.8 million Americans are estimated to suffer from GAD, with about half not responding to first-line treatments like SSRIs and SNRIs.

Osmind, a public benefit corporation, is at the forefront of advancing psychiatry through its tailored software and services. Its network is the largest in the U.S. for interventional psychiatry practices, providing invaluable support to life sciences companies in developing cutting-edge treatments. Osmind's collaboration with Cybin is expected to enhance patient outcomes and practice success through its point-of-care software and real-world data.

Cybin, founded in 2019, operates across Canada, the United States, the United Kingdom, the Netherlands, and Ireland. The company is committed to reshaping mental health treatment by introducing intermittent therapies that offer long-lasting results. With promising proof-of-concept data, Cybin is focused on developing proprietary compounds like CYB003 and CYB004, which are currently undergoing clinical trials for significant mental health disorders.

In summary, the strategic partnership between Cybin and Osmind represents a significant step forward in addressing unmet needs in mental health care. By combining their resources and expertise, the two companies aim to enhance the accessibility and effectiveness of innovative mental health treatments, ultimately improving the lives of millions affected by these conditions.